Likars'ka sprava / Ministerstvo okhorony zdorov'ia Ukrainy 2011-01-01

[Cardiotoxicity of conservative treatment of solid tumors].

L A Sivak, A V Askol'skiĭ, S A Lial'kin, M Iu Klimanov, N N Maĭdanevich, N V Kasap

文献索引：Lik. Sprava (3-4) , 51-9, (2011)

全文：HTML全文

摘要

With an increasing number of long-term breast cancer survivors, the number of patients experiencing anthracycline-induced cardiotoxicity increas too. Anthracycline--and nonanthracycline-induced cardiac toxicity--clinically significant and frequent adverse event of conservative treatment of cancer. Echocardiogram and multigated acquisition (MUGA) scan--modalities that may overlook early changes that could identify patients at risk for anthracycline-related cardiotoxicity. However, monitoring cardiac function before and during therapy, continuous infusions of drugs, limiting lifetime anthracycline dose, using cardioprotectants such as dexrazoxane, and developing lipid formulations, may decreased risk of cardiotoxicity.